Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable...

Descripción completa

Detalles Bibliográficos
Autores principales: Saponaro, Mariarosaria, Annunziata, Luigi, Turla, Antonella, Viganò, Ilaria, De Laurentiis, Michele, Giuliano, Mario, Del Mastro, Lucia, Montemurro, Filippo, Puglisi, Fabio, De Angelis, Carmine, Buono, Giuseppe, Schettini, Francesco, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656848/
https://www.ncbi.nlm.nih.gov/pubmed/36362392
http://dx.doi.org/10.3390/ijms232113604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656848/
https://www.ncbi.nlm.nih.gov/pubmed/36362392
http://dx.doi.org/10.3390/ijms232113604

Ejemplares similares